乳腺癌组织雄激素受体表达与临床相关病理特征分析  

Analysis of Androgen Receptor Expression and Clinical Pathological Features in Breast Cancer Patients

作　　者：马少君[1] 樊民义[1] 康晓丽[1] 樊国峰[1] 周理乾[1] 李文生[2] MA Shao-jun;FAN Min-yi;KANG Xiao-li;FAN Guo-feng;ZHOU Li-qian;LI Wen-sheng(Department of Radiology,Shaanxi Provincial People’s Hospital,Xi’an 710068,China;Department of Pathology,Shaanxi Provincial People’s Hospital,Xi’an 710068,China)

机构地区：[1]陕西省人民医院放射科,西安710068 [2]陕西省人民医院病理科,西安710068

出　　处：《现代检验医学杂志》2019年第6期36-40,共5页Journal of Modern Laboratory Medicine

基　　金：西安市科技计划项目[编号：2017117SF/YX011(4)];陕西社发科技攻关项目(编号：2016SF-168)

摘　　要：目的分析乳腺癌患者组织雄激素受体(androgen receptor,AR)表达状况,并探讨其与常见的组织病理学参数及预后的相关性。方法选取2012~2016年经病理确诊的190例乳腺癌患者肿瘤组织标本,通过免疫组织化学方法 (IHC)检测肿瘤组织AR蛋白水平,分析AR表达与不同临床病理参数及预后的相关性。结果 190例乳腺癌组织中AR阳性表达率为80.0%,44例三阴型乳腺癌(TNBC)患者AR阳性表达率为33%;Ⅰ级和Ⅱ级组织学分级乳腺癌中AR阳性表达率84.5%,Ⅲ级组织学分级AR阳性表达率为66.7%,AR阳性乳腺癌多对应较低组织学分级,AR表达与组织学分级呈负相关(χ^2=7.136, P<0.01);雌激素受体(estrogen receptor, ER)阴性乳腺癌AR阳性表达率为60.6%,ER阳性乳腺癌AR阳性表达率为90.3%。孕激素受体(progesterone receoptor, PR)阴性乳腺癌AR阳性表达率为65.9%,PR阳性乳腺癌AR阳性表达率为90.7%,AR表达与ER表达、PR表达呈正相关(χ^2=23.773, P<0.001;χ^2=18.043, P<0.001);Ki-67<14%组乳腺癌AR阳性表达率90.3%,Ki-67≥14%组乳腺癌AR阳性表达率75.4%,AR表达与Ki-67指数呈负相关(χ^2=5.481, P<0.05);AR表达在非三阴型乳腺癌(Non-TNBC)与三阴型乳腺癌(TNBC)的差异有统计学意义(χ^2=32.209,P<0.001);AR阳性的乳腺癌患者的总生存期明显高于AR阴性者(P<0.05);AR表达在患者年龄、月经状态、肿瘤大小、腋窝淋巴结、HER-2及血管浸润差异无统计学意义(χ^2=0.022~3.558,均P>0.05)。结论 AR表达与多种临床病理因素存在相关性,AR可能是乳腺癌的预测指标及预后重要因素。Objective To detect of expression and analyse associations with common histopathological parameters in breast cancer cases and clinical outcome. Methods 190 breast spcimens were obtained breast cancer-cases confirmed by pathological diagnosis from 2012 to 2016, and formalin-fixed,paraffin –embedded samples of tumors were tested by immunohistochemistry(IHC) as a primary estimate of AR status, and evaluated the correlation between AR expression status and different clinical pathologi-cal features and clinical outcome. Results The positive expression of AR in breast cancer was 80.0%, the positive expression of AR in TNBC was 37%. The positive expression of AR was 84.5% in grade Ⅰ and grade Ⅱ breast cancer, and 66.7% in grade Ⅲ. This positive expression of AR cases mostly exhibited a lower Histological grade(χ^2=7.136, P<0.01), AR expression was inversely correlated to histological grade. The positive expression of AR was 60.6% in ER negative breast cancer versus 90.3% in ER positive breast cancer, and 65.9% in PR negative breast cancer versus 90.7% in PR positive breast cancer, AR expression was positively inverse associated with expression of hormone receptors(ER and PR) among the patients studied, AR positive expression was corresponds to ER positive expression and PR positive expressions(χ^2=23.773, P<0.001;χ^2=18.043, P<0.001). The positive expression of AR was 90.3% in breast cancer of Ki-67<14% group,while the positive expression of AR was 90.3% in breast cancer of Ki-67 ≥ 14% group,and AR expression was inversely correlated to Ki-67 expression(χ^2=5.481, P<0.05). The expression of AR were significant differences in Non-TNBC with TNBC(χ^2=32.209, P<0.001),and the overall survival(OS) of AR positive expression patients was significantly higher than AR negative expression patients(P<0.05).The expression of AR were significant differences in age, menopausal status, tumor size,axillary lymph node,HER-2,Vascular invasion(χ^2=0.022~3.558, all P>0.05). Conclusion There had correlation of many clinical

关 键 词：乳腺癌 雄激素受体 临床病理特征 预后 

分 类 号：R737.9[医药卫生—肿瘤] R730.43[医药卫生—临床医学]